Dementia
Conditions
Brief summary
The number of people suffering from dementia in Asia (22.9 million) is more than twice the numbers in Europe (10.5 million) or the Americas (9.4 million), as recorded in the global impact of dementia in the World Alzheimer Report 2015.1 This dementia tsunami will continue to rise and the estimated number is 67 million in 2050 in Asia alone, which will be 2 to 3 times higher than the estimates for Europe (19 million) or the Americas (30 million). Devising and implementing preventive strategies against dementia is of paramount importance. The proposed project will be able to establish the associations between VRFs and cognition across cohorts with cultural, ethnical, and demographical variations. This study will generate data for evidence-based knowledge for globally implementable and effective preventive strategies for cognitive impairment and dementia.
Detailed description
Participants will be retrospectively selected from a Hong Kong Chinese cohort, a Singaporean cohort, a British cohort, two European cohorts, and an Australian cohort. Subjects from the above listed cohorts who fit the study criteria will be selected for this study. Demographical information, clinical, vascular risk factors, MRI images and cognitive data will be retrieved from the cohorts.
Interventions
None listed
Sponsors
The University of New South Wales
University of Oxford
University College, London
Umeå University
Max Planck Institute for Human Development
National University of Singapore
Chinese University of Hong Kong
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
60 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
1. Elderly community-dwelling individuals aged over 60 years old; 2. those with at least 2 time points of detailed cognitive measurements, with 2-3 years of assessment interval; 3. with at least 1 timepoint of MRI (T1, FLAIR, and DTI).
Exclusion criteria
1. subjects with stroke, dementia, and other neurological diseases at baseline; 2. those without longitudinal cognitive data; 3. those without MRI data available.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Record of blood pressure | Baseline | Blood pressure, as one of vascular risk factors, unit as mmHg |
| Record of any vascular risk factors | Baseline | medical history of hypertension, diabetes mellitus, hyperlipidemia, smoking and drinking, record unit as yes or no |
| Record of triglyceride level | Baseline | triglyceride level, as one of vascular risk factors, unit as mmol/L |
| Record of pulse | Baseline | Pulse rate, as one of vascular risk factors, unit as bpm |
| Record of high-density-lipoprotein level, | Baseline | high-density-lipoprotein level, as one of the vascular risk factors, unit as mmol/L |
| Record of low-density-lipoprotein level, | Baseline | low-density-lipoprotein level, as one of the vascular risk factors, unit as mmol/L |
| Record of total cholesterol level, | Baseline | total cholesterol level, as one of the vascular risk factors, unit as mmol/L |
| Record of glycated hemoglobin | Baseline | glycated hemoglobin, as one of the vascular risk factors, unit as percentage |
| Record of fasting blood glucose | Baseline | fasting blood glucose from blood results, as one of vascular risk factors, unit as mmol/L |
| Change of Mini-Mental State Examination | Baseline and 3rd year follow up | Mini-Mental State Examination is used for measuring general cognition including the domains of attention and processing speed, executive function, memory, visuospatial function, and animal fluency. |
| Change of Montreal Cognitive Assessment | Baseline, 1 yr, 2yr and 3rd year follow ups | Montreal Cognitive Assessment is used for measuring general cognition including the domains of attention and processing speed, executive function, memory, visuospatial function, and animal fluency. |
| Changes of brain white matter abnormalities | Baseline and 1 yr, 2yr and 3rd year follow ups | brain white matter abnormalities can be observed through the FLAIR sequence of brain MRI images |
Countries
Hong Kong
Outcome results
None listed